Letrozole-induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting.
enthesitis-related arthritis
female
inflammatory arthritis
letrozole
tendinopathy
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
07
05
2023
received:
21
02
2023
accepted:
09
05
2023
medline:
2
11
2023
pubmed:
23
5
2023
entrez:
23
5
2023
Statut:
ppublish
Résumé
Musculoskeletal symptoms associated with the use of aromatase inhibitors are a well-known side effect of these drugs and are more prevalent in postmenopausal women. Aromatase inhibitor-associated symptoms are not overt inflammatory processes so are described as arthralgia syndrome. In contrast, aromatase inhibitor-associated inflammatory conditions such as myopathies, vasculitis, and rheumatoid arthritis were also reported. To our knowledge, inflammatory arthritis or tendinopathy associated with aromatase inhibitors were not reported in children despite their increased off-label use in the pediatric setting. Herein, we report a girl with inflammatory arthritis and tendinopathy associated with letrozole treatment.
Identifiants
pubmed: 37218595
doi: 10.1111/1756-185X.14748
doi:
Substances chimiques
Letrozole
7LKK855W8I
Aromatase Inhibitors
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2314-2316Informations de copyright
© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Adwan MH. An update on drug-induced arthritis. Rheumatol Int. 2016;36:1089-1097.
Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics. Nat Rev Endocrinol. 2011;8:135-147.
Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017;3:e000523.
Bertolini E, Letho-Gyselinck H, Prati C, Wendling D. Rheumatoid arthritis and aromatase inhibitors. Joint Bone Spine. 2011;78:62-64.
Trancart M, Cavailhes A, Balme B, Skowron F. Anastrozole-induced subacute cutaneous lupus erythematosus. Br J Dermatol. 2008;158:628-629.
Santoro S, Santini M, Pepe C, et al. Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis. J Eur Acad Dermatol Venereol. 2011;25:596-598.
Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol. 2007;34:2259-2263.
Bowman S, Lu H. Aromatase inhibitor-induced inflammatory myopathies: a case series. Joint Bone Spine. 2022;89:105308.
Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16:223-234.
Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115:3631-3639.
Kirchgesner T, Larbi A, Omoumi P, et al. Drug-induced tendinopathy: from physiology to clinical applications. Joint Bone Spine. 2014;81:485-492.
Colbert RA. Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol. 2010;6:477-485.
de Carvalho HM, Bortoluzzo AB, Gonçalves CR, et al. Gender characterization in a large series of Brazilian patients with spondyloarthritis. Clin Rheumatol. 2012;31:687-695.
Jeong H, Bae EK, Kim H, et al. Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model. Arthritis Res Ther. 2017;19:198.
Lintermans A, Laenen A, Van Calster B, et al. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol. 2013;24:350-355.